Jiangsu Hengrui Medicine Co Ltd 2023 SR
The report highlights Jiangsu Hengrui Pharmaceuticals' sustainability progress in 2023, focusing on corporate governance, environmental protection, and social responsibility. The company achieved an 'A' rating from MSCI and successfully launched three Class 1 innovative drugs. Environmentally, it fulfilled 110.3% of its energy consumption targets and recycled 18,800 cubic meters of organic solutions. Socially, 103 products were included in national medical insurance, and the company donated over RMB 100 million to public welfare. It also maintained a global R&D team of over 5,000 individuals and conducted nearly 300 clinical trials.
Company: Jiangsu Hengrui Medicine Co Ltd
Sector: Health Care
Country: China
Year: 2023
Type: SR
Pages: 60
Jiangsu Hengrui Medicine Co Ltd
ESG Report
The report highlights Jiangsu Hengrui Pharmaceuticals' sustainability progress in 2023, focusing on corporate governance, environmental protection, and social responsibility. The company achieved an 'A' rating from MSCI and successfully launched three Class 1 innovative drugs. Environmentally, it fulfilled 110.3% of its energy consumption targets and recycled 18,800 cubic meters of organic solutions. Socially, 103 products were included in national medical insurance, and the company donated over RMB 100 million to public welfare. It also maintained a global R&D team of over 5,000 individuals and conducted nearly 300 clinical trials.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Apr 16, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees